| Title: |
One-month DAPT after biodegradable-polymer everolimus-eluting stent implantation in women at high-bleeding risk: Insights from the POEM trial |
| Authors: |
Maurina M.; Pivato C. A.; Kunadian V.; Testa L.; Briguori C.; Pacchioni A.; Latini A. C.; Cesani N.; Piccolo R.; Musto C.; Sardella G.; Indolfi C.; Regazzoli D.; Paradies V.; Stefanini G. |
| Contributors: |
Maurina, M.; Pivato, C. A.; Kunadian, V.; Testa, L.; Briguori, C.; Pacchioni, A.; Latini, A. C.; Cesani, N.; Piccolo, R.; Musto, C.; Sardella, G.; Indolfi, C.; Regazzoli, D.; Paradies, V.; Stefanini, G. |
| Publication Year: |
2024 |
| Collection: |
IRIS Università degli Studi di Napoli Federico II |
| Subject Terms: |
biodegradable polymer; high bleeding risk; percutaneous coronary intervention; sex; short DAPT; women |
| Description: |
Aims: We conducted a prespecified subanalysis of the POEM trial to assess the association between sex and clinical outcomes following a short 1-month dual-antiplatelet-therapy (DAPT) period after percutaneous coronary intervention (PCI) with bioresorbable polymer everolimus-eluting stent (BP-EES) among patients at high bleeding risk (HBR). Background: Shortening the DAPT period after PCI is an effective bleeding avoidance strategy with contemporary drug-eluting stents. Whether sex affects the risk of adverse events following PCI is still debated. Methods: Patients at HBR undergoing PCI with BP-EES were enrolled and treated with 1-month DAPT. If anticoagulation was needed, study participants received an oral anticoagulant (OAC) in addition to a P2Y12 inhibitor for 1 month, followed by OAC only thereafter. The primary endpoint was a composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis at 12 months. We report sex-based outcomes of patients included in the POEM study. Results: We enrolled 129 (29.1%) women and 314 (70.9%) men. Women were older, with lower hemoglobin levels, and worse renal function. Accordingly, they had a trend for a greater number of HBR criteria fulfilled and a higher PARIS bleeding score. However, they were not at a significantly higher risk for the primary endpoint (men vs. women: 5.17% vs. 3.94%; HR 1.30; 95% CI: 0.48-3.54, p = 0.61), or any of the hemorrhagic and ischemic secondary endpoints. Conclusions: This prespecified subanalysis of the POEM trial suggests that 1-month DAPT following PCI with BP-EES may be a safe and effective therapeutic strategy for women at HBR. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
volume:104; issue:6; firstpage:1129; lastpage:1138; numberofpages:10; journal:CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS; https://hdl.handle.net/11588/993915 |
| DOI: |
10.1002/ccd.31255 |
| Availability: |
https://hdl.handle.net/11588/993915; https://doi.org/10.1002/ccd.31255 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: |
edsbas.56820C86 |
| Database: |
BASE |